| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.36B | +26.9% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.02B | +36.1% |
| Gross margin | 18.5% | Net margin 6.4% |
| Revenue Q/Q | -15.7% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.29B | 81.5% |
| R&D | ¥0.01B | 1.9% |
| SG&A | ¥0.02B | 5.5% |
| Tax & other | ¥0.00B | 1.0% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
鸿富瀚 ・ 可孚医疗 ・ 戎美股份 ・ 拓新药业 ・ 华润材料 ・ 深城交 ・ 争光股份 ・ 华兰股份 ・ 广立微 ・ 百诚医药 ・ 天益医疗 ・ 金埔园林
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies